A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback